Introduction {#S0001}
============

The transforming growth factor β (TGF-β) signaling system plays an important role in carcinogenesis \[[@CIT0001]\]. Alteration of TGF-β receptors is a potential mechanism of TGF-β growth inhibitory signals and the development and progression of human cancers \[[@CIT0002]\]. The TGFBR1 gene is located on chromosome 9 \[[@CIT0003]\]. One commonly studied polymorphism of TGFBR1 is Int7G24A (rs334354), which could lead to a G to A substitution in intron 7 \[[@CIT0004], [@CIT0005]\]. Several studies have investigated the association between Int7G24A and cancer risk, and a meta-analysis by Zhang 6 years ago found that Int7G24A was a low-penetrance tumor susceptibility allele that predisposes to carcinogenesis of non-small cell lung cancer (NSCLC), kidney and bladder malignancies \[[@CIT0006]\]. However, there have been more studies about it, and the results are still inconclusive. So we performed a meta-analysis again to derive a more precise estimation of this relationship.

Material and methods {#S0002}
====================

Search strategy {#S20003}
---------------

We carried out a literature search using the PubMed database (up to January 2012) to identify all papers that investigated the association between the Int7G24A polymorphism (rs334354) and cancer risk in all ethnic groups, using combinations of the search terms "Int7G24A" and "polymorphism" and "cancer". We evaluated the titles and abstracts of all relevant publications, but excluded abstracts, case reports, editorials, and review articles.

Inclusion criteria {#S20004}
------------------

The inclusion criteria were: (1) evaluation of the Int7G24A polymorphism and cancer risk, (2) case-control studies, (3) sufficient published data about genotype frequency.

Data extraction {#S20005}
---------------

We followed a standard protocol for data extraction. The following data were collected from each study: the first author, publication date, country, ethnicity of the study population, cancer types, the number of cases and controls, and numbers of every genotype, respectively.

Statistical analysis {#S20006}
--------------------

The strength of the association between Int7G24A polymorphism and cancer was measured by the odds ratio (OR), which was calculated according to the method of Woolf \[[@CIT0007]\]. A χ^2^-based Q statistic test was performed to assess the between-study heterogeneity \[[@CIT0008]\]. Owing to the low power of the statistic, heterogeneity was considered significant for *p* \< 0.10. A fixed effects model using the Mantel-Haenszel method or a random-effects model using the DerSimonian and Laird method was used to pool the results \[[@CIT0009]\]. The significance of the pooled OR was determined by the *Z*-test. Publication bias was investigated by using a funnel plot, in which the standard error of log (OR) of each study was plotted against its log (OR). Funnel plot asymmetry was further assessed by the method of Egger\'s linear regression test \[[@CIT0010]\].

Results {#S0007}
=======

Based on our search criteria, 9 publications were identified \[[@CIT0004], [@CIT0005], [@CIT0011]--[@CIT0017]\]. Among them, 1 publication included 2 case-control studies \[[@CIT0011]\]. Hence, 9 publications including 10 studies were included in the final meta-analysis. In total, these studies included 2398 cases and 3465 controls. There were 2 studies concerning breast cancer, 3 concerning colorectal cancer, 1 concerning non-small lung cancer, 1 concerning renal cell carcinoma, 1 concerning transitional cell carcinoma, and 1 concerning osteosarcoma. All studies presented the numbers of G/G, G/A, and A/A genotypes separately. The characteristics of these studies are listed in [Table I](#T0001){ref-type="table"}.

###### 

Characteristics of case-control studies included in Int7G24A polymorphism and cancer risk

  No.   First author                Year   Country   Cancer types                  Cases   Controls                    
  ----- --------------------------- ------ --------- ----------------------------- ------- ---------- ---- ----- ----- ----
  1     Chen \[[@CIT0004]\]         1999   Holland   Cervical cancer               9       7          0    24    12    2
  2     Zhang \[[@CIT0005]\]        2003   China     Non-small cell lung cancer    18      24         11   31    52    6
  3     Chen \[[@CIT0011]\]         2004   USA       Renal cell carcinoma          46      36         4    81    32    0
  4     Chen \[[@CIT0011]\]         2004   USA       Transitional cell carcinoma   33      28         4    81    32    0
  5     Chen \[[@CIT0012]\]         2006   USA       Breast cancer                 120     92         11   113   37    3
  6     Song \[[@CIT0013]\]         2007   Sweden    Breast cancer                 500     238        29   559   265   29
  7     Lundin \[[@CIT0014]\]       2009   Sweden    Colorectal cancer             135     67         12   559   265   29
  8     Castillejo \[[@CIT0015]\]   2009   Spain     Colorectal cancer             296     178        30   333   156   15
  9     Foresti \[[@CIT0016]\]      2010   Sweden    Colorectal cancer             220     68         14   382   179   20
  10    Hu \[[@CIT0017]\]           2010   China     Osteosarcoma                  100     57         11   115   48    5

Meta-analysis results {#S20008}
---------------------

The main results of this meta-analysis and the heterogeneity test are shown in [Table II](#T0002){ref-type="table"}. When all 10 studies were pooled into the meta-analysis, significantly elevated cancer risk was associated with Int7G24A of TGFBR1 (A vs. G: OR = 1.35, 95% CI = 1.10-1.66, [Figure 1](#F0001){ref-type="fig"}; A/A+G/A vs. G/G: OR = 1.34, 95% CI = 1.05-1.72, [Figure 2](#F0002){ref-type="fig"}).
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###### 

Summary ORs and 95% CI of TGFBR1 polymorphism and cancer risk

  Analysis model    OR     95% CI      Value of *p*
  ----------------- ------ ----------- --------------
  A vs. G           1.35   1.10-1.66   0.004
  A/A+G/A vs. G/G   1.34   1.05-1.72   0.02

Value of p for heterogeneity

Sensitivity analysis {#S20009}
--------------------

A single study involved in the meta-analysis was deleted each time to reflect the influence of the individual data-set on the pooled ORs. None of the results were materially altered (data not shown).

Publication bias {#S20010}
----------------

The shapes of the funnel plots did not reveal obvious asymmetry (figures not shown). Also the results of Egger\'s test did not suggest any evidence of publication bias (*p* =0.10 for A vs. G, *p* =0.15 for A/A+G/A vs. G/G).

Discussion {#S0011}
==========

Cancer is one of the leading causes of mortality worldwide now. However, the mechanism of carcinogenesis, which may be triggered by genetic as well as environmental factors, is still not fully understood \[[@CIT0018]\]. In recent years, many candidate genes have been reported to be involved in cancer susceptibility, including p53 \[[@CIT0019]\], SPINK1 \[[@CIT0020]\], TGF-β \[[@CIT0001]\], and so on.

We all know the TGF-β signaling pathway is implicated in the pathogenesis of carcinogenesis. In this pathway, TGF-β binds directly to TGFBR2, and is then recognized by TGFBR1, which is phosphorylated and activated by TGFBR2 \[[@CIT0021]\]. Upon binding of TGF-β to its receptors, receptor-regulated Smad2/3 proteins become phosphorylated and associate with Smad4, and then translocate to the nucleus, where they regulate transcription of specific genes \[[@CIT0022], [@CIT0023]\].

TGFBR1 is crucial in the development and progression of cancer. A number of studies were reported to assess the effects of TGFBR1 polymorphism (TGFBR1\*6A) on cancer risk \[[@CIT0024]\], and this relationship was confirmed in a recent meta-analysis \[[@CIT0025]\]. With respect to another single-nucleotide polymorphism (SNP), Int7G24A (rs334354), a meta-analysis by Zhang in 2005 showed that it is associated with increased cancer risk \[[@CIT0006]\]. But there have been more studies about it, and the results are still inconclusive. Therefore, a meta-analysis was needed to confirm the association of the Int7G24A polymorphism with cancer risk.

Our pooled results, which included 2398 cases and 3465 controls, concerning seven kinds of cancers, indicated that the Int7G24A polymorphism was associated with cancer risk. The Int7G24A allele contrast (A) has a 35% increased risk of cancer, and the Int7G24A variant genotypes (both heterozygous G/A and homozygous A/A) have a 34% increased risk of cancer.

In conclusion, considering the limited studies and population numbers included in the meta-analysis, and the fact that studies with negative results are less likely to be published, further studies are encouraged to better identify these findings.

Despite these limitations, this meta-analysis confirms that Int7G24A polymorphism is associated with increased cancer risk.
